Mereo BioPharma Group (LON:MPH) Announces Quarterly Earnings Results

Mereo BioPharma Group (LON:MPH) issued its quarterly earnings data on Tuesday. The company reported GBX (105) (($1.37)) earnings per share (EPS) for the quarter, Digital Look Earnings reports.

MPH stock remained flat at $GBX 44.50 ($0.58) during midday trading on Thursday. The company had a trading volume of 25,427 shares, compared to its average volume of 418,529. The stock’s fifty day moving average is GBX 45.17 and its 200-day moving average is GBX 35.06. The stock has a market capitalization of $150.73 million and a PE ratio of -1.15. Mereo BioPharma Group has a 52-week low of GBX 13 ($0.17) and a 52-week high of GBX 69 ($0.90). The company has a debt-to-equity ratio of 80.53, a quick ratio of 0.94 and a current ratio of 1.02.

Mereo BioPharma Group Company Profile

Mereo BioPharma Group plc, a specialty biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of rare and specialty diseases. Its product candidates include BPS-804, a monoclonal antibody, which is in Phase IIb clinical trial for the treatment of osteogenesis imperfecta; AZD-9668, an oral small molecule that has been completed Phase I clinical trial to treat Alpha-1 antitrypsin deficiency; BGS-649, an oral aromatase inhibitor, which is in Phase IIb clinical trial for the treatment of hypogonadal hypogonadism; and BCT-197, an oral p38 MAP kinase inhibitor that is in Phase II clinical trial to treat acute exacerbations of chronic obstructive pulmonary disease.

Read More: Why are analyst ratings important in trading stocks?

Receive News & Ratings for Mereo BioPharma Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mereo BioPharma Group and related companies with MarketBeat.com's FREE daily email newsletter.